HDAC6—an emerging target against chronic myeloid leukemia?

Hélène Losson; Michael Schnekenburger; Mario Dicato; Marc Diederich

doi:10.3390/cancers12020318

HDAC6—an emerging target against chronic myeloid leukemia?

Hélène Losson, Michael Schnekenburger, Mario Dicato, Marc Diederich^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

17 Citations (Scopus)

Abstract

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

Original language	English
Article number	318
Journal	Cancers
Volume	12
Issue number	2
DOIs	https://doi.org/10.3390/cancers12020318
Publication status	Published - Feb 2020
Externally published	Yes

Keywords

Heat shock protein 90α
Histone deacetylase 6 inhibitor
Imatinib resistance
Leukemia stem cells
Personalized treatment
Targeted therapy

Access to Document

10.3390/cancers12020318

Cite this

@article{1a5a68febff44da89d5f5c861e494316,

title = "HDAC6—an emerging target against chronic myeloid leukemia?",

abstract = "Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.",

keywords = "Heat shock protein 90α, Histone deacetylase 6 inhibitor, Imatinib resistance, Leukemia stem cells, Personalized treatment, Targeted therapy",

author = "H{\'e}l{\`e}ne Losson and Michael Schnekenburger and Mario Dicato and Marc Diederich",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = feb,

doi = "10.3390/cancers12020318",

language = "English",

volume = "12",

journal = "Cancers",

issn = "2072-6694",